$IRWD
IRONWOOD PHARMACEUTICALS INC

2012 Form 10-K Financial Statement

#000104746913001388 Filed on February 21, 2013

View on sec.gov

Income Statement

Concept 2012 2011 Q4 2011 Q3
Revenue $150.2M $32.15M $12.22M
YoY Change 128.09% 91.39% 34.87%
Cost Of Revenue $965.0K $0.00
YoY Change
Gross Profit $149.3M $32.20M
YoY Change 126.53%
Gross Profit Margin 99.36% 100.14%
Selling, General & Admin $92.54M $15.00M $10.90M
YoY Change 101.52% 80.72% 67.69%
% of Gross Profit 61.99% 46.58%
Research & Development $113.5M $24.20M $22.91M
YoY Change 31.8% 13.62% 22.21%
% of Gross Profit 76.01% 75.16%
Depreciation & Amortization $11.33M $2.700M $2.300M
YoY Change 13.26% 35.0% 53.33%
% of Gross Profit 7.59% 8.39%
Operating Expenses $206.0M $39.20M $33.83M
YoY Change 56.05% 32.43% 34.13%
Operating Profit -$72.76M -$7.000M -$21.62M
YoY Change 10.01% 33.72%
Interest Expense $59.00K $100.0K $16.00K
YoY Change -6.35% -50.0% -80.25%
% of Operating Profit
Other Income/Expense, Net $138.0K $58.00K $986.0K
YoY Change -89.33% -94.2% 821.5%
Pretax Income -$72.62M -$7.000M -$20.63M
YoY Change 11.99% -40.17% 28.47%
Income Tax $0.00 $0.00 $3.000K
% Of Pretax Income
Net Earnings -$72.62M -$7.000M -$20.60M
YoY Change 11.98% -40.17% 205.32%
Net Earnings / Revenue -48.34% -21.77% -168.6%
Basic Earnings Per Share -$0.68 -$0.07 -$0.21
Diluted Earnings Per Share -$0.68 -$0.07 -$0.21
COMMON SHARES
Basic Shares Outstanding 100.2M shares
Diluted Shares Outstanding 100.2M shares

Balance Sheet

Concept 2012 2011 Q4 2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $168.2M $164.0M $175.1M
YoY Change 2.56% -33.87% -30.18%
Cash & Equivalents $113.9M $87.28M $68.82M
Short-Term Investments $31.50M $76.70M $106.3M
Other Short-Term Assets $8.000M $2.900M $2.900M
YoY Change 175.86% -64.2% -60.81%
Inventory $6.700M $0.00
Prepaid Expenses
Receivables $1.500M $74.00K $700.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $184.4M $167.6M $178.8M
YoY Change 10.02% -35.32% -32.09%
LONG-TERM ASSETS
Property, Plant & Equipment $37.50M $33.63M $32.90M
YoY Change 11.61% -2.16% -1.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.900M $138.0K $7.800M
YoY Change 1.28% -49.64% -2.5%
Total Long-Term Assets $45.50M $41.41M $40.70M
YoY Change 9.9% -2.08% -1.21%
TOTAL ASSETS
Total Short-Term Assets $184.4M $167.6M $178.8M
Total Long-Term Assets $45.50M $41.41M $40.70M
Total Assets $229.9M $209.0M $219.5M
YoY Change 10.0% -30.66% -27.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $21.70M $6.436M $2.400M
YoY Change 239.06% 49.6% -59.32%
Accrued Expenses $26.80M $11.12M $16.90M
YoY Change 48.07% 24.43% 42.02%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $300.0K $200.0K $200.0K
YoY Change 50.0% 0.0% 0.0%
Total Short-Term Liabilities $54.90M $65.13M $70.85M
YoY Change -15.67% 1.1% 26.97%
LONG-TERM LIABILITIES
Long-Term Debt $300.0K $400.0K $500.0K
YoY Change -25.0% 0.0% 25.0%
Other Long-Term Liabilities $30.60M $33.60M $35.20M
YoY Change -8.93% -56.36% -56.11%
Total Long-Term Liabilities $30.90M $34.00M $35.70M
YoY Change -9.12% -56.07% -55.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $54.90M $65.13M $70.85M
Total Long-Term Liabilities $30.90M $34.00M $35.70M
Total Liabilities $85.90M $99.10M $106.6M
YoY Change -13.32% -30.11% -21.9%
SHAREHOLDERS EQUITY
Retained Earnings -$432.4M
YoY Change 17.64%
Common Stock $542.1M
YoY Change 2.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $144.1M $109.9M $112.9M
YoY Change
Total Liabilities & Shareholders Equity $229.9M $209.0M $219.5M
YoY Change 10.0% -30.66% -27.92%

Cashflow Statement

Concept 2012 2011 Q4 2011 Q3
OPERATING ACTIVITIES
Net Income -$72.62M -$7.000M -$20.60M
YoY Change 11.98% -40.17% 205.32%
Depreciation, Depletion And Amortization $11.33M $2.700M $2.300M
YoY Change 13.26% 35.0% 53.33%
Cash From Operating Activities -$69.63M -$7.700M -$25.40M
YoY Change -7.45% 1183.33% 11.4%
INVESTING ACTIVITIES
Capital Expenditures $13.98M -$3.700M -$500.0K
YoY Change 44.38% 76.19% -92.31%
Acquisitions
YoY Change
Other Investing Activities $44.10M $29.10M $46.10M
YoY Change -64.64% -336.59% -13.35%
Cash From Investing Activities $30.08M $25.60M $45.50M
YoY Change -73.86% -277.78% -2.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $85.23M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $88.97M 600.0K 600.0K
YoY Change 2739.87% -25.0% -200.0%
NET CHANGE
Cash From Operating Activities -$69.63M -7.700M -25.40M
Cash From Investing Activities $30.08M 25.60M 45.50M
Cash From Financing Activities $88.97M 600.0K 600.0K
Net Change In Cash $49.42M 18.50M 20.70M
YoY Change 15.03% -230.28% -11.16%
FREE CASH FLOW
Cash From Operating Activities -$69.63M -$7.700M -$25.40M
Capital Expenditures $13.98M -$3.700M -$500.0K
Free Cash Flow -$83.61M -$4.000M -$24.90M
YoY Change -1.54% -366.67% 52.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
65134000 USD
CY2012Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
7509000 USD
CY2011Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
422000 USD
CY2011Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
76734000 USD
CY2012Q2 dei Entity Public Float
EntityPublicFloat
1323551816 USD
CY2012 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
CY2011Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
74000 USD
CY2012 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87282000 USD
CY2011Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
578000 USD
CY2011Q4 us-gaap Assets Current
AssetsCurrent
167567000 USD
CY2012 dei Entity Registrant Name
EntityRegistrantName
IRONWOOD PHARMACEUTICALS INC
CY2012 dei Entity Central Index Key
EntityCentralIndexKey
0001446847
CY2012 dei Document Type
DocumentType
10-K
CY2012 dei Document Period End Date
DocumentPeriodEndDate
2012-12-31
CY2012 dei Amendment Flag
AmendmentFlag
false
CY2012 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2012 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2012 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2012 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2012 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2012Q4 us-gaap Assets Current
AssetsCurrent
184440000 USD
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2899000 USD
CY2012Q4 us-gaap Inventory Net
InventoryNet
6699000 USD
CY2011Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
7647000 USD
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33625000 USD
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
138000 USD
CY2011Q4 us-gaap Assets
Assets
208977000 USD
CY2012Q4 us-gaap Assets
Assets
229907000 USD
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6436000 USD
CY2011Q4 irwd Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
7010000 USD
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11122000 USD
CY2011Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
233000 USD
CY2011Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
4042000 USD
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
36291000 USD
CY2012Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2011Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2011Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2012Q4 irwd Number Of Series Of Common Stock
NumberOfSeriesOfCommonStock
2 item
CY2012Q4 irwd Class Of Warrant Or Right Minimum Percentage Of Beneficial Ownership In Common Stock
ClassOfWarrantOrRightMinimumPercentageOfBeneficialOwnershipInCommonStock
0.30 pure
CY2012 irwd Common Stock Conversion Ratio
CommonStockConversionRatio
1 pure
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
136700000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44321000 USD
CY2011Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
12435000 USD
CY2011Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
21130000 USD
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
54938000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
144052000 USD
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
208977000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
229907000 USD
CY2011Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
542141000 USD
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-432392000 USD
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6000 USD
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
109856000 USD
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
75000000 shares
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
75000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012 us-gaap Revenues
Revenues
150245000 USD
CY2011 us-gaap Revenues
Revenues
65871000 USD
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86093000 USD
CY2012 us-gaap Cost Of Revenue
CostOfRevenue
965000 USD
CY2010 us-gaap Revenues
Revenues
43857000 USD
CY2010 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
77454000 USD
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-66142000 USD
CY2010 us-gaap Operating Income Loss
OperatingIncomeLoss
-60766000 USD
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-72762000 USD
CY2011 us-gaap Interest Expense
InterestExpense
63000 USD
CY2010 us-gaap Interest Expense
InterestExpense
196000 USD
CY2011 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
456000 USD
CY2010 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
614000 USD
CY2011 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
900000 USD
CY2010 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
993000 USD
CY2011 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1293000 USD
CY2010 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1411000 USD
CY2010 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
1121000 USD
CY2011 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-64852000 USD
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-64849000 USD
CY2010 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-59355000 USD
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000 USD
CY2010 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2944000 USD
CY2010 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-56411000 USD
CY2010 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-52981000 USD
CY2010 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
4551000 USD
CY2011 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-64852000 USD
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
138000 USD
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-72624000 USD
CY2012 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-72624000 USD
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-72624000 USD
CY2011 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.65
CY2010 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.63
CY2010 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.04
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2010 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2012 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.68
CY2012 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1000 USD
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72625000 USD
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64847000 USD
CY2010 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52980000 USD
CY2009Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-298340000 USD
CY2010Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
159551000 USD
CY2011Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
109856000 USD
CY2012Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
144052000 USD
CY2012 irwd Adjustment To Additional Paid In Capital Restricted Stock Subject To Repurchase
AdjustmentToAdditionalPaidInCapitalRestrictedStockSubjectToRepurchase
-7000 USD
CY2010 irwd Stock Issued During Period Value Stock Options Exercised And Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndValueEmployeeStockPurchasePlan
2023000 USD
CY2011 irwd Stock Issued During Period Value Stock Options Exercised And Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndValueEmployeeStockPurchasePlan
3393000 USD
CY2012 irwd Stock Issued During Period Value Stock Options Exercised And Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndValueEmployeeStockPurchasePlan
4020000 USD
CY2010 irwd Stock Issued During Period Value Stock Award
StockIssuedDuringPeriodValueStockAward
259000 USD
CY2011 irwd Stock Issued During Period Value Stock Award
StockIssuedDuringPeriodValueStockAward
30000 USD
CY2012 irwd Stock Issued During Period Value Stock Award
StockIssuedDuringPeriodValueStockAward
30000 USD
CY2010 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
203167000 USD
CY2010 us-gaap Share Based Goods And Nonemployee Services Transaction Stockholders Equity
ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity
123000 USD
CY2011 us-gaap Share Based Goods And Nonemployee Services Transaction Stockholders Equity
ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity
152000 USD
CY2012 us-gaap Share Based Goods And Nonemployee Services Transaction Stockholders Equity
ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity
60000 USD
CY2010 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7114000 USD
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11550000 USD
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17483000 USD
CY2010 irwd Adjustments To Additional Paid In Capital Sharebased Compensation From Discontinued Operations
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationFromDiscontinuedOperations
59000 USD
CY2010 irwd Adjustment To Additional Paid In Capital Vesting Of Restricted Stock No Longer Subject To Repurchase
AdjustmentToAdditionalPaidInCapitalVestingOfRestrictedStockNoLongerSubjectToRepurchase
55000 USD
CY2011 irwd Adjustment To Additional Paid In Capital Vesting Of Restricted Stock No Longer Subject To Repurchase
AdjustmentToAdditionalPaidInCapitalVestingOfRestrictedStockNoLongerSubjectToRepurchase
27000 USD
CY2012 irwd Adjustment To Additional Paid In Capital Vesting Of Restricted Stock No Longer Subject To Repurchase
AdjustmentToAdditionalPaidInCapitalVestingOfRestrictedStockNoLongerSubjectToRepurchase
7000 USD
CY2010 us-gaap Noncontrolling Interest Decrease From Deconsolidation
NoncontrollingInterestDecreaseFromDeconsolidation
1400000 USD
CY2011 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
5000 USD
CY2010 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1000 USD
CY2012 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1000 USD
CY2012 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
85228000 USD
CY2012 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
5900000 USD
CY2012 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-20000 USD
CY2010 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-51859000 USD
CY2012 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-72625000 USD
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
17573000 USD
CY2011 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-64847000 USD
CY2012 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1157000 USD
CY2010 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
12400000 USD
CY2011 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9999000 USD
CY2010 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6161000 USD
CY2011 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-7000 USD
CY2010 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-474000 USD
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
11732000 USD
CY2010 us-gaap Share Based Compensation
ShareBasedCompensation
7496000 USD
CY2011 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2234000 USD
CY2010 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1619000 USD
CY2011 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-2243000 USD
CY2010 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-2324000 USD
CY2011 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-2833000 USD
CY2010 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
2348000 USD
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2421000 USD
CY2010 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2647000 USD
CY2011 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-136000 USD
CY2010 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
253000 USD
CY2011Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2011 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5086000 USD
CY2010 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2740000 USD
CY2011 irwd Increase Decrease In Accrued Research And Development Expense
IncreaseDecreaseInAccruedResearchAndDevelopmentExpense
-1130000 USD
CY2010 irwd Increase Decrease In Accrued Research And Development Expense
IncreaseDecreaseInAccruedResearchAndDevelopmentExpense
-4261000 USD
CY2011 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-45012000 USD
CY2010 us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
-4532000 USD
CY2010 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-23569000 USD
CY2011 irwd Increase Decrease In Deferred Rent Payables
IncreaseDecreaseInDeferredRentPayables
-934000 USD
CY2010 irwd Increase Decrease In Deferred Rent Payables
IncreaseDecreaseInDeferredRentPayables
6745000 USD
CY2011 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-75237000 USD
CY2010 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-61930000 USD
CY2010 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-5969000 USD
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-75237000 USD
CY2010 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-67899000 USD
CY2011 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
97511000 USD
CY2010 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
441799000 USD
CY2011 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
222254000 USD
CY2010 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
236475000 USD
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9682000 USD
CY2010 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17220000 USD
CY2011 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
4000 USD
CY2010 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000 USD
CY2010 us-gaap Proceeds From Divestiture Of Interest In Consolidated Subsidiaries
ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries
9500000 USD
CY2011 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
115065000 USD
CY2010 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-213043000 USD
CY2010 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
1000 USD
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
115065000 USD
CY2010 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-213042000 USD
CY2012 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6699000 USD
CY2012 us-gaap Interest Paid
InterestPaid
55000 USD
CY2011 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3133000 USD
CY2010 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
203233000 USD
CY2010 us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
-277000 USD
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3133000 USD
CY2010 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
202956000 USD
CY2011 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
42961000 USD
CY2010 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-77985000 USD
CY2011 us-gaap Interest Paid
InterestPaid
64000 USD
CY2010 us-gaap Interest Paid
InterestPaid
325000 USD
CY2011 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3000 USD
CY2011 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
325000 USD
CY2010 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
529000 USD
CY2010 irwd Debt And Interest Paid By Purchaser Of Subsidiary
DebtAndInterestPaidByPurchaserOfSubsidiary
1075000 USD
CY2012 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
49418000 USD
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
30078000 USD
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
30078000 USD
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-69633000 USD
CY2012 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
96709000 USD
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-69633000 USD
CY2009Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
122306000 USD
CY2012 us-gaap Nature Of Operations
NatureOfOperations
<div style='font-size:10.0pt;FONT-FAMILY: Times New Roman;'> <p style="FONT-FAMILY: times"><font size="2"><b>1. Nature of Business</b></font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Ironwood Pharmaceuticals,&#160;Inc. (the "Company") is an entrepreneurial pharmaceutical company focused on the discovery, development and commercialization of medicines that improve patients' lives.</font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company's lead product, linaclotide, is being marketed in the United States ("U.S.") under the trademarked name of LINZESS&#8482;. On August&#160;30, 2012, the United States Food and Drug Administration ("FDA") approved LINZESS as a once-daily treatment for adult men and women suffering from irritable bowel syndrome with constipation ("IBS-C") or chronic idiopathic constipation ("CIC"). LINZESS is the first FDA-approved guanylate cyclase type-C ("GC-C") agonist. The Company and its collaboration partner, Forest Laboratories,&#160;Inc. ("Forest") began commercial sale of LINZESS in December 2012.</font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In November 2012, the European Commission granted marketing approval to linaclotide for the symptomatic treatment of moderate to severe IBS-C in adults. Linaclotide will be marketed in Europe (including the Commonwealth of Independent States and Turkey) by Almirall,&#160;S.A. ("Almirall") under the trademarked name of Constella&#174;.</font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Astellas Pharma&#160;Inc. ("Astellas"), the Company's partner for Japan and certain other Asian countries, is developing linaclotide for the treatment of patients with IBS-C in its territory. In October 2012, Astellas initiated a double-blind, placebo controlled, dose-ranging Phase&#160;2 clinical trial of linaclotide in adult patients with IBS-C.</font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In October 2012, the Company entered into a collaboration agreement with AstraZeneca AB ("AstraZeneca") to co-develop and co-commercialize linaclotide for IBS-C in China, Hong Kong and Macau. In May 2012, the Company submitted a Clinical Trial Application ("CTA") to China's State Food and Drug Administration for a Phase&#160;3 trial of linaclotide in patients with IBS-C. The CTA has been approved.</font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company continues to assess alternatives to bring linaclotide to IBS-C and CIC sufferers in the parts of the world outside of its partnered territories.</font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company is exploring development opportunities to strengthen the clinical profile of LINZESS within its indicated population and to expand the product label for additional patient populations and indications. The Company is also exploring the potential for linaclotide-based combination products. As part of this strategy, the Company and Forest initiated a Phase&#160;3b clinical trial to further characterize the effect of linaclotide on abdominal symptoms in patients with CIC.</font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In addition to exploring further linaclotide development opportunities, the Company's research and development team has generated a pipeline of early development candidates and discovery research in multiple therapeutic areas, including gastrointestinal disease, central nervous system disorders, allergic conditions and cardiovascular disease.</font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prior to September 2010, the Company held a majority ownership interest in Microbia,&#160;Inc. (formerly known as Microbia Precision Engineering), a subsidiary formed in September 2006. Microbia,&#160;Inc. ("Microbia") engaged in a specialty biochemicals business based on a proprietary strain-development platform. In September 2010, the Company sold its interest in Microbia to DSM Holding Company USA,&#160;Inc. ("DSM") (Note&#160;2).</font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company was incorporated in Delaware on January&#160;5, 1998. On April&#160;7, 2008, the Company changed its name from Microbia,&#160;Inc. to Ironwood Pharmaceuticals,&#160;Inc. The Company currently operates in one reportable business segment&#160;-&#160;human therapeutics. Prior to September&#160;21, 2010, the Company operated in two reportable business segments, human therapeutics and biomanufacturing (Note&#160;17).</font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company has generated an accumulated deficit as of December&#160;31, 2012 of approximately $505.0&#160;million since inception. In February 2010, the Company completed its initial public offering of Class&#160;A common stock and raised a total of approximately $203.2&#160;million in net proceeds. Additionally, in February 2012, the Company sold 6,037,500 shares of its Class&#160;A common stock through a follow-on public offering and raised a total of approximately $85.2&#160;million in net proceeds (Note&#160;12).</font></p></div>
CY2012Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2012Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.42
CY2012 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-505016000 USD
CY2012 us-gaap Use Of Estimates
UseOfEstimates
<div style='font-size:10.0pt;FONT-FAMILY: Times New Roman;'> <p style="FONT-FAMILY: times"><font size="2"><b>Use of Estimates</b></font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. ("GAAP") requires the Company's management to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company's management evaluates its estimates, including those related to revenue recognition, available-for-sale securities, inventory valuation and related reserves, impairment of long-lived assets, income taxes including the valuation allowance for deferred tax assets, research and development expense, contingencies and share-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</font></p></div>
CY2012Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
113900000 USD
CY2011Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
77200000 USD
CY2012 irwd Available For Sale Threshold Months
AvailableForSaleThresholdMonths
P3M
CY2012 us-gaap Profit Loss
ProfitLoss
-72624000 USD
CY2010 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
3430000 USD
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19619659 shares
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16584913 shares
CY2010 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14888189 shares
CY2011Q4 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
76734000 USD
CY2012Q4 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
31528000 USD
CY2011Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
76728000 USD
CY2011Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
16000 USD
CY2011Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
10000 USD
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
31523000 USD
CY2012Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
6000 USD
CY2012Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
1000 USD
CY2012 irwd Available For Sale Securities Debt Maturity Period Range High
AvailableForSaleSecuritiesDebtMaturityPeriodRangeHigh
P1Y
CY2011Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions
12 item
CY2011Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
35500000 USD
CY2012Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions
3 item
CY2012Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
3000000 USD
CY2011Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
59380000 USD
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
74517000 USD
CY2011Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
25755000 USD
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
36980000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37537000 USD
CY2011 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
2104000 USD
CY2011Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7525000 USD
CY2011Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
820000 USD
CY2011Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2777000 USD
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14594000 USD
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1031000 USD
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5546000 USD
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21171000 USD
CY2012 us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
17500000 USD
CY2012Q4 irwd Long Term Purchase Commitment Amount First Full Fiscal Year
LongTermPurchaseCommitmentAmountFirstFullFiscalYear
16900000 USD
CY2012Q4 irwd Long Term Purchase Commitment Amount Second Full Fiscal Year
LongTermPurchaseCommitmentAmountSecondFullFiscalYear
9600000 USD
CY2012Q4 irwd Long Term Purchase Commitment Amount Third Full Fiscal Year
LongTermPurchaseCommitmentAmountThirdFullFiscalYear
9700000 USD
CY2012Q4 irwd Long Term Purchase Commitment Amount Fourth Full Fiscal Year
LongTermPurchaseCommitmentAmountFourthFullFiscalYear
9700000 USD
CY2012Q4 irwd Long Term Purchase Commitment Amount Fifth Full Fiscal Year
LongTermPurchaseCommitmentAmountFifthFullFiscalYear
5900000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
11517000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
13072000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
14152000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
15255000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
15778000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
604000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
70378000 USD
CY2012Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
312000 USD
CY2012Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
253000 USD
CY2012Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
85000 USD
CY2012Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
650000 USD
CY2012Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
81000 USD
CY2012Q4 us-gaap Capital Lease Obligations
CapitalLeaseObligations
569000 USD
CY2010Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
75000000 shares
CY2012Q4 irwd Percentage Of Number Of Class B Common Stock Shares Outstanding Immediately Following Initial Public Offering Used To Determine Date Of Conversion
PercentageOfNumberOfClassBCommonStockSharesOutstandingImmediatelyFollowingInitialPublicOfferingUsedToDetermineDateOfConversion
0.25 pure
CY2011 irwd Income Tax Reconciliation Nondeductible Expense And Tax Exempt Income
IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome
245000 USD
CY2011 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-3531000 USD
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17573000 USD
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11732000 USD
CY2010 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7496000 USD
CY2011 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
3000 USD
CY2011 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-22050000 USD
CY2011 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
-509000 USD
CY2011 irwd Income Tax Reconciliation Expiring Net Operating Losses And Tax Credits
IncomeTaxReconciliationExpiringNetOperatingLossesAndTaxCredits
803000 USD
CY2011 irwd Income Tax Reconciliation Change In Enacted State And Local Tax Rates
IncomeTaxReconciliationChangeInEnactedStateAndLocalTaxRates
98000 USD
CY2011 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
20955000 USD
CY2011 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
870000 USD
CY2011 irwd Income Tax Reconciliation Income Tax Expense Benefit Before Consideration Of Income From Discontinued Operations
IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeConsiderationOfIncomeFromDiscontinuedOperations
3000 USD
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-24692000 USD
CY2010 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-20181000 USD
CY2012 irwd Income Tax Reconciliation Nondeductible Expense And Tax Exempt Income
IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome
288000 USD
CY2010 irwd Income Tax Reconciliation Nondeductible Expense And Tax Exempt Income
IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome
-3126000 USD
CY2012 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-3835000 USD
CY2010 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-3427000 USD
CY2012 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
3531000 USD
CY2010 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-243000 USD
CY2012 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
10420000 USD
CY2012 irwd Income Tax Reconciliation Expiring Net Operating Losses And Tax Credits
IncomeTaxReconciliationExpiringNetOperatingLossesAndTaxCredits
564000 USD
CY2010 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
2041000 USD
CY2010 irwd Income Tax Reconciliation Expiring Net Operating Losses And Tax Credits
IncomeTaxReconciliationExpiringNetOperatingLossesAndTaxCredits
912000 USD
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
34577000 USD
CY2010 irwd Income Tax Reconciliation Change In Enacted State And Local Tax Rates
IncomeTaxReconciliationChangeInEnactedStateAndLocalTaxRates
613000 USD
CY2010 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
27608000 USD
CY2012 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-13000 USD
CY2010 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-115000 USD
CY2010 irwd Income Tax Reconciliation Intraperiod Tax Allocation Income From Discontinued Operations Tax Benefit
IncomeTaxReconciliationIntraperiodTaxAllocationIncomeFromDiscontinuedOperationsTaxBenefit
2944000 USD
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
127928000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
24444000 USD
CY2012Q4 irwd Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
17305000 USD
CY2012Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
8300000 USD
CY2012Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
25036000 USD
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
203013000 USD
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
203013000 USD
CY2011Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
91031000 USD
CY2011 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5000 USD
CY2011Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
14024000 USD
CY2011Q4 irwd Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
22589000 USD
CY2011Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
22555000 USD
CY2011Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
17980000 USD
CY2011Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
168179000 USD
CY2011Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
168179000 USD
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
34800000 USD
CY2011 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
20300000 USD
CY2012Q4 irwd Excess Tax Benefit From Share Based Compensation Not Recognized
ExcessTaxBenefitFromShareBasedCompensationNotRecognized
24400000 USD
CY2012 irwd Defined Contribution Plan Employer Matching Contribution Employee Contribution Percent
DefinedContributionPlanEmployerMatchingContributionEmployeeContributionPercent
0.75 pure
CY2012 irwd Defined Contribution Plan Employer Matching Contribution Employee Contribution Maximum
DefinedContributionPlanEmployerMatchingContributionEmployeeContributionMaximum
6000 USD
CY2012 irwd Revenue From Continuing And Discontinued Operations
RevenueFromContinuingAndDiscontinuedOperations
150245000 USD
CY2012 irwd Income Loss From Continuing And Discontinued Operations
IncomeLossFromContinuingAndDiscontinuedOperations
-72762000 USD
CY2011 irwd Revenue From Continuing And Discontinued Operations
RevenueFromContinuingAndDiscontinuedOperations
65871000 USD
CY2011 irwd Income Loss From Continuing And Discontinued Operations
IncomeLossFromContinuingAndDiscontinuedOperations
-66142000 USD
CY2010 irwd Revenue From Continuing And Discontinued Operations
RevenueFromContinuingAndDiscontinuedOperations
45842000 USD
CY2010 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
1985000 USD
CY2010 irwd Income Loss From Continuing And Discontinued Operations
IncomeLossFromContinuingAndDiscontinuedOperations
-65298000 USD
CY2012Q4 irwd Assets From Human Therapeutics Segment
AssetsFromHumanTherapeuticsSegment
229907000 USD
CY2011Q4 irwd Assets From Human Therapeutics Segment
AssetsFromHumanTherapeuticsSegment
208977000 USD
CY2010 irwd Federal Grant Awarded
FederalGrantAwarded
1000000 USD
CY2012Q4 us-gaap Grants Receivable
GrantsReceivable
1700000 USD
CY2012 irwd Minimum Period For Which Jobs Must Be Maintained
MinimumPeriodForWhichJobsMustBeMaintained
P5Y
CY2011Q1 us-gaap Revenues
Revenues
10237000 USD
CY2011Q2 us-gaap Revenues
Revenues
11262000 USD
CY2011Q3 us-gaap Revenues
Revenues
12218000 USD
CY2011Q4 us-gaap Revenues
Revenues
32154000 USD
CY2011Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
141000 USD
CY2011Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
108000 USD
CY2011Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
986000 USD
CY2011Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
58000 USD
CY2011Q4 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-6974000 USD
CY2011Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-18401000 USD
CY2011Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-18844000 USD
CY2011Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-20633000 USD
CY2012Q1 us-gaap Revenues
Revenues
12248000 USD
CY2012Q2 us-gaap Revenues
Revenues
14604000 USD
CY2012Q3 us-gaap Revenues
Revenues
96413000 USD
CY2012Q4 us-gaap Revenues
Revenues
26980000 USD
CY2012Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
45000 USD
CY2012Q4 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-43855000 USD
CY2012Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
27000 USD
CY2012Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
31000 USD
CY2012Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
35000 USD
CY2012Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-35601000 USD
CY2012Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-40803000 USD
CY2012Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
47635000 USD
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2010 us-gaap Profit Loss
ProfitLoss
-51860000 USD
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
85228000 USD
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
88973000 USD
CY2012 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
247000 USD
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
88973000 USD
CY2012Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
261000 USD
CY2012Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
308000 USD
CY2010 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
1121000 USD
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
106402639 shares
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
99874790 shares
CY2010 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89653364 shares
CY2010 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
2944000 USD
CY2011 us-gaap Profit Loss
ProfitLoss
-64852000 USD
CY2010 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
203167000 USD
CY2011 irwd Proceeds From Stock Options Exercised And Essp And Issuance Of Restricted Stock
ProceedsFromStockOptionsExercisedAndESSPAndIssuanceOfRestrictedStock
3393000 USD
CY2010 irwd Proceeds From Stock Options Exercised And Essp And Issuance Of Restricted Stock
ProceedsFromStockOptionsExercisedAndESSPAndIssuanceOfRestrictedStock
2023000 USD
CY2011 us-gaap Repayments Of Debt
RepaymentsOfDebt
260000 USD
CY2010 us-gaap Repayments Of Debt
RepaymentsOfDebt
1957000 USD
CY2012Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2012Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.44
CY2012Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2011Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2011Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2011Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2011Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2012 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2011Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2011 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
CY2010 us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
298350000 USD
CY2012 irwd Collaboration Expense
CollaborationExpense
16030000 USD
CY2012Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2012Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2011 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
CY2012 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2012 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
140757000 USD
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11325000 USD
CY2012 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
835000 USD
CY2010Q3 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2012Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
31528000 USD
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
457000 USD
CY2012Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
1030000 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8026000 USD
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
7647000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
283000 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14217000 USD
CY2012Q4 irwd Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
5664000 USD
CY2012Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
2735000 USD
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3381000 USD
CY2012Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
11593000 USD
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
18024000 USD
CY2012 us-gaap Costs And Expenses
CostsAndExpenses
223007000 USD
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
648955000 USD
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5000 USD
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
113474000 USD
CY2012 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
92538000 USD
CY2011 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
45920000 USD
CY2010 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
27169000 USD
CY2012 us-gaap Interest Expense
InterestExpense
59000 USD
CY2012 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
197000 USD
CY2010 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1000 USD
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5127000 USD
CY2012 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
145000 USD
CY2012 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
24241000 USD
CY2012 irwd Increase Decrease In Accrued Research And Development Expense
IncreaseDecreaseInAccruedResearchAndDevelopmentExpense
-1346000 USD
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-36016000 USD
CY2012 irwd Increase Decrease In Deferred Rent Payables
IncreaseDecreaseInDeferredRentPayables
-2149000 USD
CY2012 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
992000 USD
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13979000 USD
CY2012 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
9000 USD
CY2012 irwd Proceeds From Stock Options Exercised And Essp And Issuance Of Restricted Stock
ProceedsFromStockOptionsExercisedAndESSPAndIssuanceOfRestrictedStock
4020000 USD
CY2012 us-gaap Repayments Of Debt
RepaymentsOfDebt
275000 USD
CY2011Q4 us-gaap Grants Receivable
GrantsReceivable
900000 USD
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
992000 USD
CY2011 us-gaap Costs And Expenses
CostsAndExpenses
132013000 USD
CY2010 us-gaap Costs And Expenses
CostsAndExpenses
104623000 USD
CY2011Q1 us-gaap Costs And Expenses
CostsAndExpenses
28779000 USD
CY2011Q2 us-gaap Costs And Expenses
CostsAndExpenses
30214000 USD
CY2011Q3 us-gaap Costs And Expenses
CostsAndExpenses
33834000 USD
CY2011Q4 us-gaap Costs And Expenses
CostsAndExpenses
39186000 USD
CY2012Q4 us-gaap Costs And Expenses
CostsAndExpenses
70880000 USD
CY2012Q1 us-gaap Costs And Expenses
CostsAndExpenses
47884000 USD
CY2012Q2 us-gaap Costs And Expenses
CostsAndExpenses
55438000 USD
CY2012Q3 us-gaap Costs And Expenses
CostsAndExpenses
48805000 USD
CY2012 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
89800000 USD
CY2012 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
51000000 USD
CY2011 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
212300000 USD
CY2011 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
10000000 USD
CY2012Q4 irwd Threshold Number Of Class B Common Stock Shares Outstanding Used To Determine Date Of Conversion
ThresholdNumberOfClassBCommonStockSharesOutstandingUsedToDetermineDateOfConversion
19561556 shares

Files In Submission

Name View Source Status
0001047469-13-001388-index-headers.html Edgar Link pending
0001047469-13-001388-index.html Edgar Link pending
0001047469-13-001388.txt Edgar Link pending
0001047469-13-001388-xbrl.zip Edgar Link pending
a2212263z10-k.htm Edgar Link pending
a2212263zex-10_12.htm Edgar Link pending
a2212263zex-10_155.htm Edgar Link pending
a2212263zex-10_156.htm Edgar Link pending
a2212263zex-10_4.htm Edgar Link pending
a2212263zex-10_5.htm Edgar Link pending
a2212263zex-10_91.htm Edgar Link pending
a2212263zex-21_1.htm Edgar Link pending
a2212263zex-23_1.htm Edgar Link pending
a2212263zex-31_1.htm Edgar Link pending
a2212263zex-31_2.htm Edgar Link pending
a2212263zex-32_1.htm Edgar Link pending
a2212263zex-32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
g325863.jpg Edgar Link pending
g988098.jpg Edgar Link pending
irwd-20121231.xml Edgar Link completed
irwd-20121231.xsd Edgar Link pending
irwd-20121231_cal.xml Edgar Link unprocessable
irwd-20121231_def.xml Edgar Link unprocessable
irwd-20121231_lab.xml Edgar Link unprocessable
irwd-20121231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending